RNA-seq immune subtyping to optimize immunotherapy in mNSCLCDiscovery of molecular signatures that stratify real-world survival in lung cancerINDICATIONLungBIOMARKERTIGITRelated casesIL33 expression as a predictor of immunotherapy response in NSCLCImpact of B cell and CD8 T cell infiltration on immunotherapy outcomes in NSCLCImpact of VEGF expression on pembrolizumab outcomes in mNSCLC
